UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 31, 2002
King Pharmaceuticals,Inc.
(Exact name of registrant as specified in its charter)
| Tennessee (State or other jurisdiction of incorporation) |
0—24425 (Commission File Number) |
54-1684963 (IRS Employer Identification Number) |
| 501 Fifth Street, Bristol, Tennessee (Address of principal executive offices) |
37620 (Zip Code) |
Registrant’s telephone number, including area code: 423-989-8000
Not Applicable
(Former name or former address, if changed since last report)
| SIGNATURE | ||||||||
| Exhibit Index | ||||||||
| PRESS RELEASE | ||||||||
Item 5. Other Events
On December 31, 2002, we issued a press release announcing the company’s acquisition of the rights to three branded prescription pharmaceutical products from Aventis.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(a) Financial Statements on Businesses Acquired.
| None. |
(b) Pro Forma Financial Information.
| None. |
(c) Exhibits.
| The following exhibits are filed pursuant to Item 601 of Regulation S-K: |
Exhibits:
| Exhibit | ||||||||
| Number | Description of Exhibit | |||||||
99.1 |
Press Release of King Pharmaceuticals, Inc. dated December 31, 2002. | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 31, 2002
| KING PHARMACEUTICALS, INC. |
| By: /s/ James R. Lattanzi James R. Lattanzi Chief Financial Officer |
Exhibit Index
| Exhibit | ||||||||
| Number | Description of Exhibit | |||||||
99.1 |
Press release issued by King Pharmaceuticals on December 31, 2002. | |||||||